Electrodes & Refractories company RHI Magnesita India announced Q1FY26 results Shipment volumes increased by 4%QoQ. Revenue at Rs 960 crore, increased by 5% QoQ. EBITDA at Rs 103 crore, higher by 10% QoQ. PBT at Rs 48 crore, higher by 27% QoQ. A consistent reduction in Net Debt to EBITDA, improving from 0.3x to 0.2x. Acquisition of Ashwath Technologies at Rs 14 crore on 1st August, 2025 to strengthen steel flow control machinery capabilities in India. Parmod Sagar, Chairman, MD & CEO of RHI Magnesita India, said: “Our Q1FY26 performance underscores the strength of our operating model, even in a highly commoditized and uncertain market. Our resilience is paying off where we are able to gain market share and improve our financial results. Refractory market remains competitive, but we are confident in our market positioning & strategic levers to drive growth, improving our productivity and performing safe operations at all our locations. We are also happy to share a historic milestone of deploying a full end to end robotic solution in a continuous casting system in one of the largest steel plants in India as a testament to our focus on 4PRO business model. We will deploy such business models in many more plants.” Result PDF
Conference Call with Poly Medicure Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Aegis Logistics Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Construction & Engineering company Sanathan Afcons Infrastructure announced Q1FY26 results Total income reached Rs 3,419 crore, reflecting top-line growth of 6.4% YoY. EBITDA for the quarter jumped to Rs 445 crore, reflecting a 20% YoY growth. EBITDA margin surged by 144bps YoY to 13.0% PAT showed 50% YoY improvement to reach Rs 137 crore. PAT margin also expanded by 110 bps to reach 4.0% Order book stood at Rs 35,311 crore at the end of Jun’25 providing us healthy visibility to drive topline growth Subramanian Krishnamurthy, Executive Vice Chairman (Whole-time Director), said: “Afcons Infrastructure has started the new financial year with a positive set of results, which positions us well for the rest of FY26. We have delivered good growth in our profitability metrics. In Q1FY26, our total income reached Rs 3,419 crore, reflecting top-line growth of 6.4% YoY. The corresponding EBITDA grew by 20% YoY, with margins expanding to 13.0% vs 11.6% achieved in Q1FY25. Our profit after tax grew by 50.0% YoY, and PAT margins improved by 110 bps to reach 4% vs 2.9% in Q1FY25 . This reflects the robustness of our business model. The order inflow of Rs 1,093 crore led to a pending order book of Rs 35,311 crore, excluding L1 projects worth Rs 21,556 crore (as on date). Our order book continues to remain high quality and healthy with a book to bill ratio of 2.6x, providing a good near-term revenue visibility. Our sustained efforts to make an entry in European markets bore fruits with us becoming L1 in multiple large orders in croreoatia. This is in-line with our strategy of focusing on large orders and expanding our presence in overseas markets. We are excited by the growth opportunities available both domestically and internationally. We believe that our consistent financial performance including a sturdy margin profile, positions us well to deliver value to our shareholders. We will continue to remain disciplined in our bidding and financing decisions while focusing on growth.” Result PDF
Conference Call with Century Plyboards (India) Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Supplies company Poly Medicure announced Q1FY26 results Total Income: Rs 444.9 crore compared to Rs 401.7 crore during Q1FY25, change 10.7%. EBITDA: Rs 106.1 crore compared to Rs 103.8 crore during Q1FY25, change 2.1%. EBITDA Margin: 26.3% for Q1FY26. PAT: Rs 93.1 crore compared to Rs 74.0 crore during Q1FY25, change 25.5%. PAT Margin: 20.9% for Q1FY26 Himanshu Baid, Managing Director, Poly Medicure, said: "We are pleased to share that we started the year on a steady note, with our Domestic revenue continuing to demonstrate strong growth momentum. This is supported by a healthy operating margin, enhanced PAT performance and significant product innovations all while continuing to invest in sustainability, scale, and future capacity through R&D; and green initiatives. Our renal division continues to grow at a robust pace, and with the commercialization of our Critical Care and Cardiology division last year, we are further expanding our presence in the larger Medical Devices industry. While short term challenges persist due to geopolitical tensions and recent tariff changes, we remain confident about the long term opportunity in for the Indian Medical Devices sector and continue to position ourselves strongly to capture that. We remain steadfast to our vision of “Serving people through innovative healthcare solutions”. Result PDF
Pharmaceuticals company Wockhardt announced Q1FY26 results Revenue for Q1FY26 is Rs 738 crore compared to Rs 747 crore in Q1FY25. EBITDA for Q1FY26 of Rs 101 crore compared to Rs 100 crore in Q1FY25. EBITDA Margin: 13.7% for Q1FY26. PBT: Rs -109 crore compared to Rs -6 crore during Q1FY25. PAT: Rs -108 crore compared to Rs -16 crore during Q1FY25. PAT Margin: -14.6% for Q1FY26. Result PDF
Holding Companies company Cholamandalam Financial Holdings announced Q1FY26 results Q1FY26 Consolidated Financial Highlights: Consolidated total income for Q1FY26 is Rs.9,383 crore as against Rs.7,677 crore in Q1FY25, registering a growth of 22%. Consolidated PAT of Rs.1,260 crore as against Rs.1,160 crore in Q1FY25, registering a growth of 9%. Q1FY26 Standalone Financial Highlights: The total income of the company for Q1FY26 is Rs.3.65 crore as against 2.58 crore for Q1FY25. PAT for Q1FY26 is Rs.2.11 crore as against Rs.1.39 crore in Q1FY25. Result PDF